Eisai Co., Ltd, (TYO: 4523) a leading Japanese pharmaceutical company, has entered into a strategic licensing agreement with compatriot Sato Pharmaceutical Co., Ltd for the development and commercial rights of the anti-fungal drug fosravuconazole in the Asia and Oceania regions. This deal includes the 10 ASEAN nations, Australia, New Zealand, South Korea, and Taiwan, significantly expanding the reach of this novel treatment.
Fosravuconazole, known to improve solubility and bioavailability, is a prodrug of ravuconazole, which was originally discovered and developed by Eisai. Sato Pharma has been marketing fosravuconazole in Japan under the trade name Nailin since July 2018 for the treatment of onychomycosis, a fungal infection of the nails. The drug has demonstrated superior efficacy and safety in phase III clinical studies.
Under the terms of the agreement, Eisai will receive undisclosed upfront and milestone payments, as well as royalties on future sales. This strategic partnership aims to maximize the value of fosravuconazole in the Asia-Pacific region, ensuring that patients suffering from fungal infections have access to this innovative treatment option.
This licensing agreement not only strengthens the collaboration between Eisai and Sato Pharma but also highlights the potential of fosravuconazole to address the growing demand for effective antifungal therapies in the region. The deal is expected to contribute to the expansion of treatment options for patients, improving clinical outcomes and quality of life .- Flcube.com
